×
About 8,458 results

ALLMedicine™ Glioblastoma Multiforme Center

Research & Reviews  2,758 results

Getting cancer research on track again may require a ‘behemoth’ effort
https://www.mdedge.com/hematology-oncology/article/257036/mixed-topics/getting-cancer-research-track-again-may-require
Monica Smith

Aug 15th, 2022 - In 2016, then–vice president Joe Biden launched Cancer Moonshot just 1 year after his son Beau died from glioblastoma multiforme. He wanted to “cure” cancer, he said.

Downregulated ferroptosis-related gene SQLE facilitates temozolomide chemoresistance, a...
https://doi.org/10.1111/cns.13945
CNS Neuroscience & Therapeutics; Yao L, Li J et. al.

Aug 14th, 2022 - Chemoresistance in patients with glioblastoma multiforme (GBM) is a common reason hindering the success of treatment. Recently, ferroptosis has been reported to be associated with chemoresistance in different types of cancer, while the role of fer...

Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies.
https://doi.org/10.1002/wnan.1838
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobio... Liu D, Dai X et. al.

Aug 13th, 2022 - Glioblastoma multiforme (GBM) represents the most common and fatal form of primary invasive brain tumors as it affects a great number of patients each year and has a median overall survival of approximately 14.6 months after diagnosis. Despite int...

The evaluation expression of non-coding RNAs in response to HSV-G47∆ oncolytic virus in...
https://doi.org/10.1007/s13365-022-01089-w
Journal of Neurovirology; Vazifehmand R, Ali DS et. al.

Aug 12th, 2022 - Glioblastoma multiforme is the most aggressive astrocytes brain tumor. Glioblastoma cancer stem cells and hypoxia conditions are well-known major obstacles in treatment. Studies have revealed that non-coding RNAs serve a critical role in glioblast...

GMI, Ganoderma microsporum protein, suppresses cell mobility and increases temozolomide...
https://doi.org/10.1016/j.ijbiomac.2022.08.024
International Journal of Biological Macromolecules; Tseng AJ, Tu TH et. al.

Aug 12th, 2022 - Glioblastoma multiforme (GBM), which is a malignant primary brain tumor, is the cancer that spreads most aggressively into the adjacent brain tissue. Patients with metastatic GBM have a poor chance of survival. In this study, we examined the anti-...

see more →

Guidelines  1 results

The role of radiotherapy in the management of progressive glioblastoma : a systematic r...
https://doi.org/10.1007/s11060-013-1337-6
Journal of Neuro-oncology; Ryu S, Buatti JM et. al.

Apr 15th, 2014 - Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiati...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  490 results

Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study
https://clinicaltrials.gov/ct2/show/NCT02302235

Aug 11th, 2022 - Primary aims of the study will be to 1) To evaluate efficacy of ketogenic diet as adjunctive treatment of radiation treatment in glioblastoma multiforme. 2) To evaluate the safety of ketogenic diet as adjunctive treatment of radiation treatment in...

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
https://clinicaltrials.gov/ct2/show/NCT04489420

Aug 10th, 2022 - This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the ...

Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT02285959

Aug 10th, 2022 - The high-grade malignant brain tumor glioblastoma multiforme (GBM) comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only...

6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)
https://clinicaltrials.gov/ct2/show/NCT04926168

Aug 10th, 2022 - Recent phase III trials in patients with newly diagnosed patients with glioblastoma have demonstrated that adding new agents (such as cilengitide, bevacizumab, or nivolumab) to standard radiation and TMZ do not improve survival in this disease. Th...

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
https://clinicaltrials.gov/ct2/show/NCT05495295

Aug 10th, 2022 - The PhAST Trial is a first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours. The trial includes two parts, a dose escalation phase (part I) which will enroll patients with non...

see more →

News  128 results

Getting cancer research on track again may require a ‘behemoth’ effort
https://www.mdedge.com/hematology-oncology/article/257036/mixed-topics/getting-cancer-research-track-again-may-require
Monica Smith

Aug 15th, 2022 - In 2016, then–vice president Joe Biden launched Cancer Moonshot just 1 year after his son Beau died from glioblastoma multiforme. He wanted to “cure” cancer, he said.

Management of Progressive Glioblastoma Clinical Practice Guidelines (CNS, 2022)
https://www.medscape.com/viewarticle/974543

May 31st, 2022 - Updated guidelines for the management of progressive glioblastoma were published in May 2022 by the Congress of Neurological Surgeons (CNS) in Neurosurgery.[1] Imaging Gadolinium contrast-enhanced magnetic resonance imaging (MRI) is recommended fo...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
https://www.onclive.com/view/fda-grants-fast-track-designation-to-cynk-101-for-her2-gastric-gej-cancers

Jan 19th, 2022 - The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab (Herceptin), and pembrolizumab (Keytruda) for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ)...

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma
https://www.onclive.com/view/fda-grants-fast-track-designation-to-st101-for-recurrent-glioblastoma

Dec 6th, 2021 - The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma, according to an announcement from Sapience Therapeutics, Inc., the drug developer.1 The decision is ...

see more →

Patient Education  1 results see all →